NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
- Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
- A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
- Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
- A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.